×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

LAICON 2022 International: ASCVD Risk Reduction in Persons with Hypertriglyceridemia- Role of Icosapent Ethyl

  339 Views

Dr Nathan D Wong, USA    08 October 2022

  • Substantial ASCVD risk persists despite low levels of LDL-C and elevated TGs, and their remnants account for a portion of this residual risk.
  • Combination therapy of statins with fibrates or niacin has not shown effectiveness and is generally not recommended to reduce ASCVD event risk.
  • REDUCE-IT was a landmark trial showing that icosapent ethyl 4 g/day in addition to maximally tolerated statin therapy could reduce ASCVD events significantly. However, its impact on TGs appears not to account for all of the substantial benefits of this therapy.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.